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Myeloid cells comprise a heterogeneous population of
cells that include granulocytes and monocytes. Recent
data reveals a complex role of myeloid cells as mediators
of tumor progression and tumor induced immunosup-
pression. Myeloid-derived suppressor cells (MDSCs)
have been extensively studied in mouse models and are
thought to be actively recruited to the tumor and sup-
press immunity through multiple mechanisms. Charac-
terizations of human MDSCs have been much more
problematic due to the lack of equivalent surface mar-
kers in mice and the variation and inconsistent use of
human cell surface markers. The use of these popula-
tions as biomarkers for immunity requires standardiza-
tion in sample prep and reporting. Typically, blood is
prepared for analysis by collection of the mononuclear
cell fraction. However, we found that this method can
alter the cell populations of interest. For example, paired
samples from healthy ten volunteers showed an increase
of CD16 expression on monocytes purified by density
gradient centrifugation versus those stained directly
from whole blood. In addition, whole blood flow cyto-
metry allows universal reporting terms as results can be
reported in cells/μL. In effort to begin to standardization
human myeloid subsets, we developed a ten color flow
panel to analyze unfractionated peripheral blood. As
part of this development, we felt it was very important
to use surface markers and non-overlapping gating stra-
tegies that would enable us to define distinct myeloid
populations. We used a combination of ten markers that
allows us to measure over 15 myeloid phenotypes includ-
ing granulocytes (using CD15, CD16 and CD66b), mono-
cyte sub-populations (identified by CD14 and CD16),
suppressive monocytes (CD14+HLA-DRlo/neg), myeloid
derived suppressor cell populations (LINnegCD33
+HLA-DR+), and circulating dendritic cell populations
(LINnegHLA-DR+ subgrouped by CD11c and CD123).
In addition to typical bivariate plotting strategies, we
also used radar plot analyses to look at multiple markers
simultaneously. Data from healthy volunteer controls
and cancer patients of the non-overlapping myeloid
populations will be shown. This approach will allow
standardization of the collection and reporting of these
critically important populations.
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